Biotech Adam Feuerstein STAT Plus: Celgene now owns a checkpoint inhibitor for solid tumors, but is Beigene deal too late for cancer immunotherapy race?
Biotech Adam Feuerstein STAT Plus: New Sarepta CEO is top drug talent with coveted commercial expertise; sell-side ‘confidence’ cliche
Biotech Adam Feuerstein STAT Plus: Merck shocks with CETP cholesterol study win; Ra Pharma’s scant PNH data
Biotech Adam Feuerstein STAT Plus: Modest clinical trial win for Seattle Genetics, New Ra Pharma data on tap
